Home / Nieuws / ...

Vitamine D bij diabetes*
Extra vitamine D kan zeer gunstig zijn voor diabetici met coronaire hartziekte zo blijkt uit een Iraanse studie. In de studie kregen 60 deelnemers 6 maanden lang of iedere twee weken 1.250 mcg vitamin D of een placebo. Na zes maanden hadden de deelnemers in de vitamine D groep duidelijk betere bloedwaarden vitamine D, bloedsuikerwaarden, gunstige effecten op de metabole profielen en flinke verlaging van markers van ontsteking en oxidatieve stress.
De studie. (April 2017)

Long-Term Vitamin D Supplementation Affects Metabolic Status in Vitamin D–Deficient Type 2 Diabetic Patients with Coronary Artery Disease1,2
1. Alireza Farrokhian3, Fariba Raygan3, Fereshteh Bahmani4, Hamid Reza Talari5, Reza Esfandiari5, Ahmad Esmaillzadeh6–8, and Zatollah Asemi4,*
+ Author Affiliations
1. 3Department of Cardiology, School of Medicine, 
2. 4Research Center for Biochemistry and Nutrition in Metabolic Diseases, and 
3. 5Department of Radiology, Kashan University of Medical Sciences, Kashan, Iran; 
4. 6Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, 
5. 7Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran; and 
6. 8Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran 
1. ↵*To whom correspondence should be addressed. E-mail: asemi_r@yahoo.com. 
Abstract
Background: Vitamin D might be beneficial in diabetic patients with coronary artery disease (CAD) through its favorable effects on metabolic profiles and biomarkers of inflammation and oxidative stress. 
Objective: This study was performed to examine the effects of 6 mo of vitamin D supplementation on metabolic status in diabetic patients with CAD. 
Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted in 60 vitamin D–deficient diabetic patients with CAD aged 40–85 y. Subjects were randomly assigned into 2 groups to take either 50,000-IU vitamin D supplements (n = 30) or placebo (n = 30) every 2 wk for 6 mo. Fasting blood samples were obtained at the beginning of the study and after the 6-mo intervention to quantify glycemic indicators, lipid concentrations, and biomarkers of inflammation and oxidative stress. 
Results: Compared with placebo, vitamin D supplementation resulted in significant reductions in fasting plasma glucose (−14.9 ± 7.1 compared with +19.3 ± 7.1 mg/dL; P = 0.001), serum insulin (−2.7 ± 1.1 compared with +1.8 ± 1.1 μIU/mL; P = 0.006), homeostasis model assessment of insulin resistance (−0.7 ± 0.3 compared with +0.5 ± 0.3; P = 0.01), and β cell function (−9.1 ± 4.2 compared with +5.7 ± 4.2; P = 0.01) and a significant increase in serum vitamin D (+6.8 ± 0.9 compared with +0.1 ± 0.9 ng/mL; P < 0.001) and the Quantitative Insulin Sensitivity Check Index (+0.008 ± 0.004 compared with −0.007 ± 0.004; P = 0.01). In addition, changes in serum high-sensitivity C-reactive protein (hs-CRP; −1.0 ± 0.5 compared with +0.6 ± 0.5 μg/mL; P = 0.02), plasma nitric oxide (NO; +7.0 ± 2.0 compared with −4.6 ± 2.0 μmol/L; P < 0.001), total reduced glutathione (GSH; +104 ± 16.4 compared with +24.8 ± 16.4 μmol/L; P = 0.001), and malondialdehyde concentrations (−0.2 ± 0.1 compared with +0.2 ± 0.1 μmol/L; P < 0.001) in the supplemented group were significantly different from the changes in these indicators in the placebo group. 
Conclusions: Overall, 6 mo of vitamin D supplementation among vitamin D–deficient diabetic patients with CAD had beneficial effects on glycemic control and serum hs-CRP, NO, GSH, and malondialdehyde concentrations. This trial was registered on the Iranian website (www.irct.ir) for registration of clinical trials as IRCT201510315623N56.